Sacubitril Valsartan Versus Mineralocorticoid Receptor Antagonists for Heart Failure Readmission Risk Across all Subtypes
Cardiology Research and Cardiovascular Medicine · 08.10.2026 · 11 (1)
DOI: 10.29011/2575-7083.100304 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiology Research and Cardiovascular Medicine, online erschienen am 08.10.2026.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Heart failure (HF) is classified as HFrEF, HFmrEF, and HFpEF.Sacubitril/valsartan improves outcomes in HFrEF, but benefits in HFmrEF and HFpEF are less clear.MRAs reduce mortality in HFrEF and hospitalizations in HFpEF.Direct comparisons across HF subtypes, especially HFmrEF, are limited.Goal: To compare sacubitril/valsartan (ARNI) based therapy, MRA based therapy, and ARNI plus MRA combination therapy in HFrEF, HFmrEF, and HFpEF, specifically evaluating their association with short term all cause readmission at 7, 15, and 30 days after discharge.This analysis was designed to assess readmission risk alone and does not evaluate mortality or symptom based outcomes.Because all patients also received background therapy with an ACE inhibitor, angiotensin receptor blocker, or beta blocker, the ARNI and MRA groups are best understood as ARNI based and MRA based regimens rather than true monotherapy.
Methods
Retrospective analysis of 23,649 adults with newly diagnosed HF from the HCA Healthcare national database (190 hospitals, ~2,400 ambulatory sites).Patients were aged 30 to 60 years, representing a comparatively younger heart failure population than most national registries, in which average age at hospitalization exceeds 70 years.Patients were stratified by EF phenotype and grouped as MRA only, ARNI only, or combination therapy; prior outpatient use was exclusionary.Readmission risks were analyzed at 7, 15, and 30 days, accounting for race and comorbidities.Baseline Characteristics: The cohort was 70.1% male, 54.2% White, 33.0%Black.Comorbidities included hypertension (65.2%), diabetes (26.3%), and CKD (17.7%).Most had HFrEF (68.3%), followed by HFmrEF (17.4%) and HFpEF (14.4%).MRA monotherapy was most frequent (64.1%).Among patients, 4,164 received ARNI, 15,162 MRA, and 4,323 combination therapy.
Results
In HFrEF, MRA based therapy increased readmission odds compared with combination therapy at 7 days (OR 1.24), 15 days (OR 1.25), and 30 days (OR 1.34).ARNI based therapy increased 30-day readmissions compared with MRA based therapy in HFrEF (OR 1.19) and HFpEF (OR 1.60).CKD increased 15-and 30-day readmissions in HFrEF.In HFpEF, African American race was linked to lower 15-and 30-day readmissions, a finding discussed further in the Discussion as a possible reflection of differential outcome ascertainment rather than a true protective effect.
Zitieren
APA
(2026). Sacubitril Valsartan Versus Mineralocorticoid Receptor Antagonists for Heart Failure Readmission Risk Across all Subtypes. Cardiology Research and Cardiovascular Medicine, 11(1). https://doi.org/10.29011/2575-7083.100304
Vancouver
Sacubitril Valsartan Versus Mineralocorticoid Receptor Antagonists for Heart Failure Readmission Risk Across all Subtypes. Cardiology Research and Cardiovascular Medicine. 2026;11(1). doi:10.29011/2575-7083.100304
BibTeX
@article{euvimed2026,
title = {Sacubitril Valsartan Versus Mineralocorticoid Receptor Antagonists for Heart Failure Readmission Risk Across all Subtypes},
journal = {Cardiology Research and Cardiovascular Medicine},
year = {2026},
volume = {11},
number = {1},
doi = {10.29011/2575-7083.100304}
}
EUVIMED